Outlining the Molecules Tested In Vivo for Chagas Disease, Malaria, and Schistosomiasis Over the Last Six Years - A Literature Review Focused on New Synthetic Drug Identities and Repurposing Strategies
- PMID: 36200257
- DOI: 10.2174/0929867329666220930112136
Outlining the Molecules Tested In Vivo for Chagas Disease, Malaria, and Schistosomiasis Over the Last Six Years - A Literature Review Focused on New Synthetic Drug Identities and Repurposing Strategies
Abstract
Background: COVID-19 disrupted NTD programs in 60% of countries, impairing public health goals. Thus, boosting NTD's research knowledge is demanding, and in vivo screening of candidates allows for the prospect of promising options based on their overall profile.
Objective: In this work, we highlighted the relevant research done between 2015-2021 in the fields of synthetic and repurposed drugs that were tested in vivo for Chagas disease, malaria, and schistosomiasis.
Methods: MEDLINE, PUBMED, CAPES PERIODIC, and ELSEVIER databases were used for a comprehensive literature review of the last 6 years of research on each area/disease.
Results: Overall, research focused on nitro heterocyclic, aromatic nitro, nucleoside, and metal-based scaffolds for analogue-based drug generation. Repurposing was widely assessed, mainly with heterocyclic drugs, their analogues, and in combinations with current treatments. Several drug targets were aimed for Chagas treatment, specific ones such as iron superoxide dismutase, and more general ones, such as mitochondrial dysfunction. For malaria, hemozoin is still popular, and for schistosomiasis, more general structural damage and/or reproduction impairment were aimed at in vitro analysis of the mechanism of action.
Conclusion: Latest in vivo results outlined trends for each disease - for Chagas Disease, heterocyclics as thiazoles were successfully explored; for Malaria, quinoline derivatives are still relevant, and for schistosomiasis, repurposed drugs from different classes outstood in comparison to synthetic compounds. This study uprises the continuous development of Chagas disease, malaria, and schistosomiasis drugs, providing researchers with tools and information to address such unmet therapeutic needs.
Keywords: Chagas disease; animal screening; malaria; repurposing; schistosomiasis; synthetic compounds.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review.Int J Antimicrob Agents. 2020 Apr;55(4):105906. doi: 10.1016/j.ijantimicag.2020.105906. Epub 2020 Jan 25. Int J Antimicrob Agents. 2020. PMID: 31987883 Review.
-
Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue.Phytother Res. 2019 Oct;33(10):2473-2517. doi: 10.1002/ptr.6383. Epub 2019 Aug 23. Phytother Res. 2019. PMID: 31441148 Review.
-
Superoxide Dismutase Inhibitors against Malaria, Leishmaniasis, and Chagas Disease: Systematic Review.Curr Drug Targets. 2023;24(2):201-210. doi: 10.2174/1389450124666221209105822. Curr Drug Targets. 2023. PMID: 36503390
-
Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.Infect Disord Drug Targets. 2013 Aug;13(4):217-77. doi: 10.2174/1871526513666131129155708. Infect Disord Drug Targets. 2013. PMID: 24304352 Review.
-
Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.Int J Mol Sci. 2020 Nov 20;21(22):8809. doi: 10.3390/ijms21228809. Int J Mol Sci. 2020. PMID: 33233837 Free PMC article.
Cited by
-
Chagas Disease across the Ages: A Historical View and Commentary on Navigating Future Challenges.Microorganisms. 2024 Jun 6;12(6):1153. doi: 10.3390/microorganisms12061153. Microorganisms. 2024. PMID: 38930535 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical